Product news

Share this article:
Eli Lilly announced that the FDA has approved Strattera (atomoxetine HCI) for maintenance treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.

Trudell Medical International announced FDA approval of Alvesco (ciclesonide) inhalation aerosol in combination with the Aerocount Dose Indicator. Alvesco, a novel inhaled corticosteroid, will be distributed in the US by Sepracor under an agreement with Nycomed based in Europe. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.